2022
Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group.
Mehra R, Flamand Y, Quon H, Garcia J, Weinstein G, Duvvuri U, O'Malley B, Ozer E, Thomas G, Koch W, Gross N, Bell R, Saba N, Lango M, Bayon R, Burtness B, Ferris R. Outcomes by tobacco history in E3311, a phase II trial of transoral surgery (TOS) followed by pathology-based adjuvant treatment in HPV-associated (HPV+) oropharynx cancer (OPC): A trial of the ECOG-ACRIN Cancer Research Group. Journal Of Clinical Oncology 2022, 40: 6077-6077. DOI: 10.1200/jco.2022.40.16_suppl.6077.Peer-Reviewed Original ResearchProgression-free survivalOropharynx cancerOverall survivalSmoking statusTransoral surgeryAdjuvant treatmentPerformance statusPrimary siteECOG-ACRIN Cancer Research GroupFirst treatment approachHistory of smokingPhase II trialKaplan-Meier methodLog-rank testCancer Research GroupSignificant differencesWilcoxon rank sum testChi-square testRank sum testDefinitive chemoradiationEvaluable ptsOS ratesEfficacy outcomesExtranodal extensionII trial
2006
A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study
Argiris A, Goldwasser M, Burtness B, Deconti R, Axelrod R, Van Waes C, Forastiere A. A phase II trial of PS-341 (bortezomib) followed by the addition of doxorubicin at progression in incurable adenoid cystic carcinoma of the head and neck: An Eastern Cooperative Oncology Group study. Journal Of Clinical Oncology 2006, 24: 5573-5573. DOI: 10.1200/jco.2006.24.18_suppl.5573.Peer-Reviewed Original ResearchStable diseaseEvaluable ptsNeutropenia 5Cystic carcinomaEastern Cooperative Oncology Group StudyECOG performance status 0Median progression-free survivalGrade 3/4 toxicitiesPerformance status 0Absolute neutrophil countPhase II trialProgression-free survivalTime of progressionAdenoid cystic carcinomaDistant metastatic sitesNF-κB activityAddition of doxorubicinBaseline tumorDiarrhea 5Measurable diseasePrior therapyStatus 0Thrombocytopenia 5Disease stabilizationII trial